G6PD Genotyping Algorithm for Therapeutic Drug Recommendations

**Key:**
CNSHA: Congenital nonspherocytic hemolytic anemia

*Variants of Uncertain (VUS) significance may be identified. If a VUS is identified, a WHO Class will not be assigned and enzyme studies are recommended.

† WHO Class I Variant: Severe G6PD enzyme deficiency (<10% activity) and chronic nonspherocytic hemolytic anemia (CNSHA)
WHO Class II/III Variant: Deficient G6PD enzyme activity (10%-60% activity)
WHO Class IV Variant: Normal G6PD enzyme activity